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Background: We determined factors associated with morbidity and outcomes of 
a series of non-small cell lung cancer (NSCLC) patients treated with dose-escalated 
chemoradiotherapy at the University of Pittsburgh Lung Cancer Program.
Methods and materials: The records of 170 stage III NSCLC patients treated with 
definitive intent were retrospectively reviewed. All patients received four-dimensional CT 
simulation scan and had respiratory gating if tumor movement exceeded 5 mm. Overall 
survival (OS), locoregional control (LRC), and freedom from distant metastasis (FFDM) 
were calculated using log-rank and Cox regression analysis.
results: For the present series of patients, median follow-up was 36.6 months, median 
survival 27.4 months, and the 2- and 4-year OS was 56.0 and 30.7%, respectively. The 
4-year LRC and FFDM were 43.9 and 40.7%, respectively. No benefit was associated with 
irradiation doses above 66 Gy in OS (p = 0.586), LRC (p = 0.440), or FFDM (p = 0.230). 
On univariate analysis, variables associated with worse survival included: clinical stage IIIB 
(p = 0.037), planning target volume (PTV) over 450 cc (p < 0.001), heart V30 over 40% 
(p = −0.048), and esophageal mean dose over 20% (p = 0.024), V5 (p = −0.015), and 
V60 (p = −0.011). On multivariable analysis, PTV above 450 cc (52.2 vs. 25.3 months, 
p < 0.001) and esophageal V60 >20% (43.8 vs. 21.3 months, p = −0.01) were associated 
with lower survival. Grade 2 or higher acute lung toxicity and esophagitis were detected in 
9.5 and 59.7%, respectively of patients. Grade 2 or higher acute lung toxicity was reduced 
if lung V5 was ≤65 (7.4 vs. 23.8%, p = 0.03). Grade 2 or higher acute esophagitis was 
reduced if V60 ≤ 20% (62 vs. 81.3%, p = 0.018). The use of intensity-modulated radiation 
therapy was more frequent in stage IIIB compared to stage IIIA patients (56.5 vs. 39.5%, 
p = 0.048) and was associated with a higher lung V5 and V10.
conclusion: The outcomes of a program of dose-escalated chemoradiotherapy for 
unresectable stage IIIA and IIIB NSCLC patients were consistent with other studies 
and showed no benefit to radiation doses above 66 Gy. Furthermore, maintaining low 
esophageal V60 and lung V5 were associated with lower morbidity and mortality.
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inTrODUcTiOn
The optimal chemoradiation therapy management of locally 
advanced non-small cell lung cancer (NSCLC) has been a subject 
of great interest (1). Even with current aggressive multi-modality 
treatment protocols, the clinical outcomes remain suboptimal 
(2). Previous clinical trials have established the superiority of 
concurrent chemoradiation using radiation doses between 60 and 
66 Gy and revealed median survival times of 16–18 months (3–5). 
Dose-escalation protocols in Phase II clinical trials revealed the 
feasibility of radiation doses up to 74  Gy and suggested some 
increase in median survival to 26 months (6). Advances in radia-
tion therapy techniques such as intensity-modulated radiation 
therapy (IMRT), three-dimensional conformal radiation therapy 
(3D-CRT), motion management, and attention to normal tissue 
dose parameters allowed dose escalation in some studies (7, 8). 
Radiation dose-escalation trials were evaluated for improved 
locoregional control (LRC) and overall survival (OS).
A recent clinical Trial from the RTOG (RTOG 0617) for 
stage IIIA/B NSCLC (2) was initiated to randomize radiation 
dose groups to cohorts of 60 Gy compared to 74 Gy each with 
similar concurrent chemotherapy. The 74-Gy arm showed 
no benefit and was associated with a survival detriment. Both 
arms had the same LRC, distant metastasis rate and measured 
toxicity; however, further analysis showed that the use of IMRT 
was associated with better patient reported quality of life, and 
also that improved baseline pretreatment QOL was predictive 
of survival (9). Other parameters influencing survival included 
low heart dose, low esophageal morbidity, and smaller planning 
target volume (PTV). Although, it is important to note, the lack 
of pretreatment quality assurance from a central review has called 
the outcomes in question, especially when it comes to delineating 
normal structures such as the heart (10, 11).
We now report the results of this single institution experience 
with definitive chemoradiation for stage IIIA and IIIB NSCLC 
and compare outcomes for patients treated with 3D-CRT com-
pared to patients treated with IMRT.
MaTerials anD MeThODs
Patient Population
We carried out a retrospective study using the criteria established 
by the American Joint Committee on Cancer (AJCC) seventh 
edition for patients with Stage IIIA and IIIB NSCLC. All patients 
were treated with definitive intent over the interval 2001–2013. 
All patients were determined to be unresectable by either: multi-
ple node positivity, contralateral or supraclavicular lymph nodes, 
or tumor invasion of adjacent organs.
Patient medical records were de-identified and analyzed with 
ethical approval by the University of Pittsburgh Institutional 
Review Board (IRB #PRO13020306). The review was done with 
compliance to our ethic standards. All patients received daily 
radiotherapy fractions using a megavoltage linear accelerator 
with photon energy above 6 MV, and either IMRT or 3D-CRT. 
Radiation therapy was delivered concurrently with dual agent 
chemotherapy. All patients received four-dimensional CT 
(4D-CT) scan to assess target motion at time of simulation. 
Respiratory gating was included in daily treatments if tumor 
movement during simulation was greater than 5  mm in any 
direction (12).
staging
The staging system for NSCLC changed during the years of the 
study, therefore, we used the AJCC seventh staging edition as a 
standard for all patients. Patients were staged using PET/CT of 
the chest, abdomen, and pelvis, brain MRI, mediastinal lymph 
node sampling, and biopsy of both primary cancer and multiple 
mediastinal lymph nodes.
Dosimetry Parameters
In general, the normal esophagus was defined as being from the 
cricopharyngeus muscle to the gastroesophageal junction and 
the lung volume including the bilateral lungs from the apex chest 
apex to the diaphragm while subtracting out the PTV. These were 
mostly already created using our treatment plan software and we 
also used paper charts to assist with determine dosimetry values. 
In general our goals were V20 for lung <30%, mean esophagus 
dose less than or equal to 35 Gy and cord dose less than or equal 
to 45 Gy. Heart dose varied based on tumor location. For IMRT 
we also added V5 <60% and V10 <40% constraints for lung. In 
our early experience, patients were treated with fixed-field IMRT 
and after expanded to both rapid arc and fixed-field IMRT.
statistical analysis
LRC, freedom from distant metastasis (FFDM), and OS were 
primary outcome measures, and were calculated using log-rank 
and Cox regression analysis from time of diagnosis. Locoregional 
control was defined as lack of progression of clinical disease, seen 
on follow-up imaging or biopsy of the radiation therapy treatment 
volume for primary and regional lymph nodes. Acute toxicity was 
evaluated using binomial regression and late toxicity evaluated 
using Cox regression, t-test, ANOVA, binomial regression, and 
linear regression analysis. Each outcome measurement was cor-
related to dosimetric variables. Multivariable analysis (MVA) was 
performed for each factor found to be significant on unvariant 
analysis (p ≤ 0.05). Statistical analysis was performed using IBM 
SPSS Statistics Version 23.
resUlTs
Patient Demographics
There were 597 patients with clinical stage IIIA or IIIB NSCLC 
in the UPCI database over the interval 2001 to 2013. Patients 
treated with palliative intent (n = 296) were excluded as were 
those receiving only surgical management (n = 28). Radiotherapy 
patients not treated with concurrent chemotherapy (n =  39) 
were excluded. The remaining cohort of 213 patients was evalu-
ated. Forty-three patients were lost to follow-up defined as no 
follow-up from treatment. Median follow-up of the cohort 
of 170 patients was 22  months and is shown in Table  1. The 
Interquartile Range (IQR) was 8.9–39.6. Median follow-up was 
TaBle 1 | Baseline characteristics for entire cohort (n = 170).
Patient variables results
age
Median and range (years) 67 (38–91)
gender
Male 111 (65.3%)
Female 59 (34.7%)
race
Caucasian 137 (80.6%)
African-American 33 (19.4%)
NOS/other
histology
Adenocarcinoma 77 (45.3%)
Squamous cell 54 (31.8%)
Large cell 10 (5.9%)
Mixed 2 (1.2%)
NSCLC/NOS 27 (15.9%)
stage
T4N0 10 (5.9%)
T3N1 3 (1.8%)
T4N1 3 (1.8%)
T0N2 8 (4.7%)
T1N2 21 (12.4%)
T2N2 36 (21.2%)
T3N2 16 (9.4%)
T4N2 20 (11.8%)
T0N3 8 (4.7%)
T1N3 11 (6.5%)
T2N3 17 (10%)
T3N3 7 (4.1%)
T4N3 10 (5.9%)
stage
IIIA 97 (57.1%)
IIIB 73 (42.9%)
chemotherapy
Carboplatin paclitaxel 150 (88.2%)
Cisplatin and etoposide 5 (2.9%)
Carboplatin and protein-bound paclitaxel 1 (0.6%)
Cisplatin and gemcitabine 1 (0.6%)
Carboplatin and pemetrexed 2 (1.2%)
Carboplatin and etoposide 5 (2.9%)
Carboplatin and docetaxel 3 (1.8%)
Cisplatin and docetaxel 3 (1.8%)
Volumes
Median GTV (cc) 84 (4–586)
Median PTV (cc) 338 (43–1303)
Technique
3D-RT 119 (70%)
IMRT 46 (27.1%)
N/A 5 (2.9%)
simulation
No gating 127 (74.7%)
Gating 23 (13.5%)
N/A 20 (11.8%)
Dose (gy)
Median and range 72 (54–84)
Dose ranges (gy)
54–66 41 (24.1%)
67–70 32 (18.8%)
71–74 51 (30%)
75–80 45 (26.5%)
81–84 1 (0.6%)
GTV, gross tumor volume; NA, not available; NSCLC, non-small cell lung cancer; NOS, 
not otherwise specified; 3D-CRT, three-dimensional conformal radiation therapy; IMRT, 
intensity-modulated radiation therapy; PTV, planning target volume.
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36.6  months (IQR, 26.6–63.7) for the subset of patients still 
living.
Treatment and Dosimetric evaluation
All patients were treated with concurrent chemoradiation, 
median radiation dose was 72 Gy (IQR, 68–77). The treatment 
volume and doses had inhomogeneity corrections. IMRT was 
used in 27.1%. All patients received a 4D-CT simulation scan, 
and 13.5% required respiratory gating. Concurrent carboplatin 
and paclitaxel were the dual agents in 88.2% of patients.
Overall survival
The median survival of the entire group was 27.4 months. There 
was a 2- and 4-year OS of 56.0 and 30.7%, respectively. On 
univariate analysis decreased survival was detected in the subset 
of patients with: (1) stage IIIB (p = 0.037), (2) PTV > 450 cc 
(p <  0.001), (3) heart V30 >  40% (p =  0.048), (4) esophageal 
mean dose of >20% (p  =  0.024), (5) esophageal V5  >  60% 
(p =  0.015), and (6) esophageal V60 >  20% (p =  0.011). On 
multivariate analysis decreased survival was detected in patients 
with a large PTV (≥450 vs. <450  cc; 52.2 vs. 25.3  months, 
p < 0.001). Esophageal volumes of V60 that were over 20% were 
also associated with reduced survival (V60 ≤  20 vs. >20; 43.8 
vs. 21.3 months, p = 0.01). Radiation dose above 66 Gy was not 
associated with improved OS (p = 0.586). Statistical analysis is 
shown in Table 2.
locoregional control
The 2-and 4-year LRC for the entire group was 54.4 and 43.9%, 
respectively. On univariate analysis, large PTV was associated 
with a reduced LRC [≤450 vs. >450 cc, HR = 1.86; 95% confi-
dence interval (CI) (1.03–3.36), p = 0.039]. Radiation dose above 
66 Gy was not associated with increased LRC (p = 0.440).
Freedom from Distant Metastasis
The percentage of 2- and 4-year FFDM was 54.4 and 40.7%, 
respectively, for the entire group. On univariate analysis, higher 
radiation therapy doses (p = 0.041) and PTV > 450 cc (p = 0.004) 
were each associated with reduced FFDM. On multivariate 
analysis, PTV above 450 cc [≤450 vs. >450 cc, HR = 2.15, 95% 
CI (1.27–3.62), p = 0.004] was associated with reduced FFDM. A 
radiation dose above 66 Gy was not associated with an improved 
FFDM (p = 0.230).
Factors influencing Toxicity
In the present series, the median value of mean lung dose was 
15.2  Gy (IQR, 13–18  Gy) and median lung V20 was 26% (IQR 
21–31%). There was grade 2 or higher acute lung toxicity detected 
in 9.5% of patients. On univariate analysis, the use of 3D-CRT 
(p = 0.036) and V5 ≤ 65 (p = 0.036) were associated with a lower 
rate of pneumonitis. On multivariate analysis, lung V5 ≤ 65 was 
associated with a decreased acute grade 2 or higher lung toxicity 
(7.4 vs. 23.8%, p = 0.027). The incidence of 1-year and 2-year late 
grade 3+ pneumonitis was 1.2 and 2.1%, respectively. There were 
no detectable univariate factors that predicted for late grade 3 or 
higher pneumonitis.
TaBle 3 | Univariate and multivariable analysis (MVa) for acute toxicity.
acute grade 2+ lung 
toxicity
acute 2+ esophagitis
3D-crT vs. iMrT hr = 3.181 (1.079–9.384), 
p = 0.036
p = 0.086
rT dose p = 0.626 hr = 1.060, 95% 
confidence interval (ci) 
(1.002–1.120, p = 0.041)
PTV p = 0.720 p = 0.951
lung
Mean p = 0.893 –
V5 ≤ 65 hr = 3.884, 95% ci 
(1.096–13.767), p = 0.036
–
V10 p = 0.377 –
V20 p = 0.345 –
V30 p = 0.895 –
esophagus
Max – 0.743
Mean – 0.077
V5 – 0.208
V60 ≤ 20 – hr = 2.2697, 95% ci 
(1.115–6.340), p = 0.027
MVa
V5 ≤ 65 7.4 vs. 23.8%, p = 0.027 –
Esophageal V60 ≤ 20 62 vs. 81.3%, p = 0.018
3D-CRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated 
radiation therapy; PTV, planning target volume, RT, radiation therapy.
TaBle 2 | Univariate and multivariable analysis (MVa) for overall survival (Os), lrc, and freedom from distant metastasis (FFDM).
Os locoregional control FFDM
Age ≤60 p = 0.373 HR = 0.614 (0.368–1.024), p = 0.062 p = 0.261
Gender p = 0.166 p = 0.408 p = 0.686
Race p = 0.742 p = 0.540 p = 0.926
Histology p = 0.155 p = 0.904 p = 0.562
IIIA vs. IIIB hr = 1.465; 95% confidence interval (ci)  
(1.024–2.096), p = 0.037
p = 0.467 hr = 0.598, 95% ci  
(0.374–0.956), p = 0.032
RT dose (continuous) p = 0.761 p = 0.706 0.511
≤66 vs. >66 Gy p = 0.586 p = 0.440 p = 0.230
3D vs. IMRT p = 0.427 p = 0.991 0.964
PTV450cc hr = 2.305, 95% ci (1.478–3.596), p < 0.001 hr = 1.860; 95% ci (1.031–3.356),  
p = 0.039
hr = 2.149, 95% ci  
(1.274–3.624), p = 0.004
lung
Mean p = 0.402 – –
V5 p = 0.584 – –
V10 p = 0.519 – –
V20 p = 0.474 – –
V30 p = 0.186 – –
heart
Maximum p = 0.242 – –
Mean p = 0.091 – –
V30 ≤ 40 hr = 1.836, 95% ci (1.005–3.353), p = 0.048 – –
esophageal
Max p = 0.408 – –
Mean ≤ 20 hr = 2.146, 95% ci (1.105–4.167), p = 0.024 – –
V5 ≤ 60 hr = 1.017, 95% ci (1.003–1.030), p = 0.015 – –
V60 ≤ 20 hr = 1.758, 95% ci (1.135–2.721), p = 0.011 – –
MVa
PTV450cc 52.2 vs. 25.3 months, p < 0.001 hr = 1.860; 95% ci (1.031–3.356),  
p = 0.039
hr = 2.149, 95% ci  
(1.274–3.624), p = 0.004
Esophageal V60 ≤ 20 43.8 vs. 21.3 months, p = 0.01 – –
3D-CRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; PTV, planning target volume; RT, radiation therapy.
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The median value for the mean esophageal dose in the group 
was 28  Gy in the present study (IQR, 21–33  Gy). The median 
esophageal V60 was 16% (IQR, 3–27%). Acute grade 2 or higher 
esophagitis was detected 59.7% of patients. On univariate 
analysis, a lower radiation therapy dose as a continuous vari-
able (p = −0.041) and esophageal V60 ≤ 20% (p = −0.027) were 
associated with lower rates of acute grade 2 or higher esophagitis. 
On multivariate analysis, esophageal V60 ≤ 20% was associated 
with a lower rate of acute grade 2 or higher esophagitis (62 vs. 
81.3%, p = 0.018). We observed late 1-year and 2-year grade 3+ 
esophagitis in 4.5 and 6.5% of patients, respectively. There was no 
detectable univariate factor that predicted late grade 3 or higher 
esophagitis (Table 3).
Utilization and Outcomes of  
3D-crT vs. iMrT
We compared factors that were associated with the radiation 
oncologist’s choice of 3D-CRT vs. IMRT for radiotherapy 
management. We found no detectable difference by patient 
age (p = 0.095), gender (p = 0.072), race (p = 0.340), histology 
(p = 0.752), RT dose (p = 0.131), respiratory gating (p = 0.105), 
or PTV (p = 0.459). IMRT use was higher in IIIB patients than 
in IIIA patients (56.5 vs. 39.5%, p = 0.048). For IIIB compared 
to IIIA patients, IMRT was associated with a higher lung V5 
(37 vs. 57%, p = 0.001) and V10 (30 vs. 43%, p = 0.002). Compared 
TaBle 4 | Dosimetric outcomes for 3D-crT vs. intensity-modulated 
radiation therapy (iMrT) in iiia and iiiB non-small cell lung cancer 
patients.
Mean p-Value
clinical iiia
lung
Mean 3D 15 0.491
IMRT 16
V5 3D 37 0.001
IMRT 57
V10 3D 30 0.002
IMRT 43
V20 3D 23 0.195
IMRT 26
V30 3D 19 0.758
IMRT 19
heart
Maximum 3D 56 0.068
IMRT 68
Mean 3D 12 0.430
IMRT 14
V30 3D 15 0.716
IMRT 17
esophagus
Max 3D 69 0.049
IMRT 74
Mean 3D 25 0.528
IMRT 27
V5 3D 57 0.288
IMRT 61
V60 3D 14 0.785
IMRT 15
clinical iiiB
lung
Mean 3D 17 0.774
IMRT 17
V5 3D 45 0.009
IMRT 59
V10 3D 33 0.004
IMRT 45
V20 3D 28 0.413
IMRT 30
V30 3D 23 0.240
IMRT 21
heart
Maximum 3D 71 0.026
IMRT 53
Mean 3D 17 0.133
IMRT 12
V30 3D 24 0.054
IMRT 13
esophagus
Max 3D 74 0.452
IMRT 72
Mean 3D 34 0.739
IMRT 33
V5 3D 66 0.087
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to patients treated with 3D-CRT, there was a lower esophageal 
mean dose for IMRT patients (69 vs. 74%, p = 0.049) (Table 4). 
The median survival for IIIB patients treated with IMRT was 
higher than those treated with 3D-CRT, but the data did not 
reach statistical significance (19.0 vs. 26.1 months, p = 0.429). 
IMRT use was also associated with improved survival for IIIA 
patients, but did not reach statistical significance (28.7 vs. 
42.3 months, p = 0.418).
DiscUssiOn
Despite advances in delivery techniques for radiation therapy, 
patients with locally advanced NSCLC have displayed sub-
optimal outcomes, and median survival remains between 15 
and 26 months (2, 13). Dose-escalation protocols for radiation 
therapy doses above 60 Gy showed a benefit, but also revealed 
increased toxicities (14). The addition of concurrent chemo-
therapy to 60 Gy radiation resulted in further improved survival 
(3–5). While some phase II studies showed the feasibility of dose-
escalated chemoradiation therapy with higher survival outcomes, 
the recent RTOG 0617 study did not confirm a benefit to the use 
of higher radiation dose (2, 6). We compared the RTOG 0617 
results with those of our single institution series at UPCI.
The median survival for the present cohort of 170 evaluable 
NSCLC stage IIIA and IIIB patients was 27.4 months. This value is 
comparable to the median survival reported in the recent RTOG 
0617 trial. In both studies, better staging with PET/CT leading 
to stage migration and improvements in treatment delivery and 
better supportive care may have accounted for the improvement 
in survival (2).
The median radiation dose delivered to patients in our single 
institution study was 72  Gy. We determined the value of dose 
escalation by comparing those patients treated to doses above 
66  Gy with those receiving doses below 66  Gy. This cut-off 
value was based upon prior clinical trials comparing sequential 
to concurrent chemoradiation (3–5). Prior trials showed that 
concurrent, dual agent, platinum-based chemotherapy was more 
effective than use of sequential single drugs in chemoradiation 
protocols (3–5). We found no benefit for those patients treated 
above 66 Gy. We also found no benefit if the radiation dose was 
analyzed as a continuous variable. Therefore, we conclude that 
our data correlate with the results of RTOG 0617 showing no 
benefit to radiation dose escalation above 66 Gy.
The present analysis revealed that PTV volumes of NSCLC 
tumor above 450 cc were associated with a lower OS, LRC, and 
FFDM, again confirming the results presented in RTOG 0617 
(2). Another clinical trial, which is a randomized phase II pro-
gram, which evaluates adaptive planning in stage IIIA/B NSCLC 
patients for dose escalation, RTOG 1106, is ongoing. The control 
arm in this new study will receive 50 Gy, then continuing to 60 Gy 
after an interim PET/CT scan. The experimental arm will receive 
46.2 Gy, then PET/CT scan evaluation, then use adaptive dose-
escalation ranges using the FDG-PET/CT scan up to a total dose 
of 80.4 Gy.
Our study revealed new information on toxicity of chemora-
diotherapy of NSCLC. Acute grade 2 or higher lung toxicity in 
9.5% patients was associated with a median lung V20 of 26 Gy. 
The data correlate well with a prior study showing that V20 
values between 22 and 31 Gy led to an 8% pneumonitis rate (8). 
FigUre 1 | comparison of the overall survival (Os), locoregional 
control (lrc), and freedom from distant metastasis (FFDM) for stage 
iiia/B non-small cell lung cancer. The median survival was 25.9 months 
for the entire cohort. Both local recurrence and distant metastasis remained a 
major factor decreasing survival.
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In this prior study (8), 42% of patients received chemotherapy 
(concurrent or sequential). In our study, the low rate of pneu-
monitis with high dose concurrent chemoradiation was likely 
attributable to 4D-CT simulation and the pre-screening of 
patients with tumor movement to include respiratory gating in 
their treatment program. Lower rates of lung toxicity were also 
detected in patients, where there was V5 ≤ 65%. A prior study 
(15), showed that V5 ≤ 42% did indeed correlate with a lower 
rate of acute pneumonitis for NSCLC patients treated with 
concurrent chemoradiation (15). A review of 220 esophageal 
cancer patients (16) also treated with radiation alone showed 
that V5 ≤ 60% correlated with lower rates of acute pneumonitis. 
We conclude that mean lung dose and lung V20 are the standard 
dosimetric parameters for predicting pneumonitis; however, 
we suggest that more attention should be given to the low dose 
volumes when treating patients with IMRT.
Esophagitis remains a serious complication of chemoradio-
therapy of NSCLC. Esophageal grade 2 or higher toxicity rate 
was observed in 59.7% of our patients. This result was consistent 
with the combined grade 2 or higher esophagitis rate of the 74 Gy 
arm (43%) in the RTOG 0617 study (2). Keeping the esophageal 
V60 ≤ 20% correlated with lower frequency of detection of acute 
grade 2 or higher esophagitis. A retrospective analysis of another 
series of 109 NSCLC patients treated with concurrent chemora-
diation showed the esophageal V60 correlated with higher rates of 
acute esophagitis (17). In yet another study, the threshold dose 
of 58 Gy predicted acute grade 3 or higher esophageal toxicity 
(18). Therefore, there is a consensus that the magnitude of the 
esophageal volume receiving more than 40–50  Gy correlates 
with the severity of acute esophagitis (19, 20). Our results sup-
port efforts to ensure that as much of the esophagus as possible 
should be spared from the high-dose region. We will plan on 
incorporating our knowledge of the esophageal V60 this into our 
treatment planning for stage III patients treated with definitive 
chemoradiation.
The RTOG 0617 study showed that the use of IMRT did 
improve the QOL in NSCLC patients and reduced rates of grade 
3 pneumonitis. In addition, there was an increased likelihood of 
completing adjuvant chemotherapy (2, 9). We found that IMRT 
use was greater for IIIB patients, likely due to the requirement 
for coverage of supraclavicular and contralateral mediastinal 
disease, while achieving acceptable V20 volumes (mean, 30%) 
and attempting to still reduce lung toxicity. IMRT treatment plans 
decreased the esophageal V60 volume and the maximum heart 
dose. There was a trend for IMRT treatment plans to decrease the 
heart V30 volume, a parameter associated with survival outcomes 
on univariate analysis, but not multivariate analysis. A lowered 
heart V30 was also associated with improved survival outcomes 
in the RTOG 0617 study (2).
There was no statistically significant increase in survival for 
IIIA or IIIB patients treated with IMRT vs. 3D-CRT, although 
median survival times were different. In a secondary analysis of 
the data in RTOG 0617, the high-dose arm was associated with a 
lower patient reported QOL at 3 months, and baseline pretreat-
ment QOL was predictive of survival (9). IMRT use was associated 
with a less deterioration of QOL compared to patients receiving 
3D-CRT. We were unable to associate use of IMRT with a possible 
survival benefit, although a trend in this direction was apparent. 
A larger study with a more balanced distribution between uses of 
IMRT compared to 3D-RT may result in a statistically significant 
difference.
Patients treated with IMRT did not show a decreased rate 
of acute esophagitis or pneumonitis. This result may have been 
attributable to a higher usage of IMRT for patients with IIIB 
disease, and the need for larger treatment volumes. Two retro-
spective reviews of NSCLC patients showed decreased rates of 
pneumonitis with use of IMRT when compared to 3D-CRT for 
NSCLC (7, 21). Radiation therapy planning comparing 3D-CRT 
to IMRT showed that IMRT also lead to a 50% relative reduction 
in predicted esophageal complications (22).
We analyzed our data using Kaplan–Meier plots, and this 
method revealed separation of the LRC and FFDM curves from 
OS (Figure 1). The data suggest that patients in our cohort may 
have died from causes other than local or distant recurrence of 
NSCLC. Since patients with aerodigestive cancers have a 3–5% 
yearly risk of a second aerodigestive primary cancer, we recom-
mend that radiation oncologists ensure that long-term follow-up 
visits include screening for second cancers.
There were limitations to our retrospective analysis of NSCLC 
patients, including: (1) single institution retrospective review, (2) 
lack of a prospective randomized trial, and (3) limited follow-up 
interval. These factors might have led to both overestimating the 
primary outcomes and underestimating late toxicity. We also 
have a limited number of patients, and thus, our reports should be 
compared with other single institution reports and randomized 
control trials. We are additionally limited since we did not have 
electronic records for most of our patients and, therefore, may 
lead unreported events. Last, our dosimetry data are based on 
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treating physicians who may have used different treatment 
considerations. We have overcome this issue by implementation 
of clinical pathways to guide our physicians and to have a more 
uniform criterion for care.
In a retrospective review of stage IIIA/B, NSCLC patients 
at UPCI larger PTV volumes and esophageal V60 >  20% were 
associated with poorer survival. Acute grade 2 or higher lung 
toxicity was lower in the V5 ≤ 65% group and acute grade 2 plus 
esophagitis was lower in the V60 ≤ 20% group. We recommend 
that patients with unresectable stage IIIA and IIIB NSCLC, who 
require radiotherapy be treated to doses not exceeding 66 Gy.
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